Investing.com - ProPhase Labs (NASDAQ: PRPH) reported third quarter EPS of $-0.300, $0.11 worse than the analyst estimate of $-0.195. Revenue for the quarter came in at $8.37M versus the consensus estimate of $13.06M.
ProPhase Labs's stock price closed at $4.730. It is down -23.090% in the last 3 months and down -57.820% in the last 12 months.
ProPhase Labs saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See ProPhase Labs's stock price’s past reactions to earnings here.
According to InvestingPro, ProPhase Labs's Financial Health score is "good performance".
Check out ProPhase Labs's recent earnings performance, and ProPhase Labs's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar